Literature DB >> 2795120

Toxicity of IL-2 and Corynebacterium parvum following direct intracranial injection.

R C Sutton1, J Kennedy, J Duncan, F K Conley.   

Abstract

The toxicity of IL-2 and/or C. Parvum when injected directly into the mouse brain was examined by survival and histopathology using different numbers of injections, different doses of IL-2, different solvents for the IL-2, and different doses and routes of administration of C. Parvum. Two injections was found significantly to increase mortality (19%) over a single injection (4%). Mortality from two injections of 30,000 U (23%) or 60,000 U (20%) was higher than from two injections of 15,000 U (12%). The mortality from two injections with normal saline as solvent was much higher (29%) than from two injections with sterile water (19%) or D5W (9%). Two injections of IL-2 given simultaneously with C. Parvum showed a much higher mortality (26%) than other doses and routes of C. Parvum administration. Mice dying acutely (6-24 days) of toxicity showed an extensive mononuclear infiltrate at the site of injection. The brains of surviving mice (sacrificed at 30 days) showed a mild residual mononuclear cell infiltrate with the exception of mice which had received IL-2 and C. Parvum simultaneously. Brains from this latter group had an extensive residual mononuclear cell infiltrate.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2795120     DOI: 10.1007/bf00172920

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  6 in total

1.  Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. Preliminary report.

Authors:  S K Jacobs; D J Wilson; P L Kornblith; E A Grimm
Journal:  J Neurosurg       Date:  1986-05       Impact factor: 5.115

2.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

Authors:  S A Rosenberg; M T Lotze; L M Muul; A E Chang; F P Avis; S Leitman; W M Linehan; C N Robertson; R E Lee; J T Rubin
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

3.  Blood-brain barrier dysfunction in cats following recombinant interleukin-2 infusion.

Authors:  M D Ellison; J T Povlishock; R E Merchant
Journal:  Cancer Res       Date:  1987-11-01       Impact factor: 12.701

4.  High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings.

Authors:  M T Lotze; A E Chang; C A Seipp; C Simpson; J T Vetto; S A Rosenberg
Journal:  JAMA       Date:  1986-12-12       Impact factor: 56.272

5.  Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.

Authors:  S E Ettinghausen; S A Rosenberg
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701

6.  Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrier.

Authors:  S C Saris; S A Rosenberg; R B Friedman; J T Rubin; D Barba; E H Oldfield
Journal:  J Neurosurg       Date:  1988-07       Impact factor: 5.115

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.